Chelsie Derman

New research links high smoke pollution to increased respiratory hospitalizations in older adults, highlighting urgent health risks from wildfires.

Johnson & Johnson announced the approval of FcRn blocker nipocalimab for adults and children > 12 years who are AChR or MuSK antibody positive.

Alto Neuroscience developed an EEG biomarker that predicts placebo response in MDD trials, potentially improving drug effect detection and reducing trial variability.

Patients with HαT showed a 13% prevalence of drug-induced anaphylaxis, with greater risk tied to antibiotic- and monoclonal antibody-triggered reactions.

A systematic review suggests introducing denatured or baked egg under supervision could reduce the burden of strict allergen avoidance.

Real-world data show omalizumab, alone or with OIT, is effective and well-tolerated for IgE-mediated food allergy, with high response rates in adults.

Xanomeline and trospium chloride failed to show significant benefit as an adjunctive schizophrenia treatment to typical antipsychotics but showed promise in select subgroups.

Tryptase, although identified as the most reliable anaphylaxis biomarker in a recent systematic review, only had a 49% sensitivity.

A survey reported that among 98.3% of respondents prescribed an epinephrine autoinjector for food allergies, 75.1% expressed concern about obtaining it.

A phase 3 trial found the Viaskin peanut patch effective in desensitizing peanut-allergic children aged 1 – 3 years, regardless of asthma, atopic dermatitis, or other food allergies.

In a recent study, a diagnostic protocol of 1:10 intradermal tests and subcutaneous provocation showed high accuracy for diagnosing immediate-type anesthetic allergy in children.

A new study identified 6 distinct CRSwNP endotype clusters, revealing that patients with mixed type 1/3 inflammation experience faster polyp recurrence than those with type 2 inflammation.

Inhalant exposure at work is linked to worse FESS outcomes in CRSwNP patients, with less symptom relief and higher polyp recurrence, a new study finds.

Combining FESS with selective vidian neurectomy improved long-term nasal symptom control, especially nasal itching, in CRSwNP, allergic rhinitis, and asthma.

Ultrasound showed no significant dermis thickness difference at the cubital fossa, yet dust mite-sensitized kids had signs of allergen-driven skin changes.

In children with septic shock, norepinephrine as the first vasoactive agent was linked to lower 30-day mortality than epinephrine, with no renal outcome difference.

In this Q&A, Augsten discusses treatment strategies, challenges, and non-pharmacological interventions for schizophrenia and bipolar I disorder based on recent survey findings.

Q1 2025 sleep updates include FDA rejecting pitolisant NDA for idiopathic hypersomnia, iptacopan improving PNH fatigue, and more.

Allergy treatment use increases postpartum depression risk in women with allergic rhinitis, a study found.

Q1 2025 featured several regulatory updates in psychiatry, such as esketamine as the first monotherapy for treatment-resistant depression.

Q1 2025 allergy updates: FDA approved the first omalizumab biosimilar, and experts shared insights on peanut immunotherapy and food allergy treatments.

The FDA granted fast-track status to Biogen’s BIIB080, a tau-targeting therapy for Alzheimer Disease, which is now being evaluated in the global phase 2 CELIA study.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

HCPLive spoke with Levine about what is moving in the psychiatry pipeline and what is to come.

Aquestive’s Anaphylm study showed positive pharmacokinetic results in children and adolescents, supporting its FDA submission.

March Allergy Updates: FDA approved the first biosimilar for omalizumab, epicutaneous and oral immunotherapy trials showed promise, and experts discussed allergy trends.